Physician profile
Roy Cohen
NPI 1194765032
$596.14
in general payments reported to CMS, 2019-2025
16 companies · $23.78 in 2025
The $23.78 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $186 · 2021: $113 · 2025: $23.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $23.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $92.08 | 2019-2021 | |
| Novo Nordisk INC | $60.45 | 2019-2021 | |
| Pfizer INC. | $58.34 | 2019-2020 | |
| Amarin Pharma, INC. | $49.71 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $48.93 | 2020-2021 | |
| Abbott Laboratories | $47.43 | 2021-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $42.48 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.06 | 2020 | |
| Amgen INC. | $35.98 | 2019-2021 | |
| Glaxosmithkline, LLC. | $20.20 | 2019 | |
| Scilex Pharmaceuticals INC. | $19.73 | 2019 | |
| Horizon Therapeutics Plc | $19.72 | 2020 | |
| Novartis Pharmaceuticals Corporation | $18.30 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.68 | 2020 | |
| Cardiovascular Systems INC. | $15.41 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.